JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
Microb Drug Resist. 2010 Mar;16(1):61-5. doi: 10.1089/mdr.2009.0031.
Enterobacteriaceae clinical isolates harboring KPC-(178 strains) or CTX-M-encoding (67 strains) genes were collected during surveillance programs in the 2000-2007 period; and susceptibility was tested by broth microdilution methods. Organisms were dominantly collected in U.S. hospitals (93%). CTX-M-15 and -14 were the most prevalent CTX-M types (97%), all collected from the United States. KPC producers were isolated in the United States (160/178), Israel, China, and Argentina. bla(CTX-M)-carrying isolates were 95.5 and 98.5%, susceptible to Imipenem and meropenem respectively, and were all susceptible to tigecycline, whereas KPC-producing isolates were highly resistant to all antimicrobials tested except polymyxin B and tigecycline (90.6% and 99.4% susceptibility, respectively). The occurrence of KPC-producing and CTX-M-producing isolates has rapidly increased especially in U.S. hospitals, and expanded therapeutic options are needed to treat infections caused by these emerging organisms.
在 2000-2007 年期间的监测项目中收集了携带 KPC-(178 株)或 CTX-M-编码(67 株)基因的肠杆菌科临床分离株;并通过肉汤微量稀释法检测了药敏性。这些生物体主要在美国医院采集(93%)。CTX-M-15 和 -14 是最常见的 CTX-M 型(97%),均来自美国。KPC 产生菌在美国(160/178)、以色列、中国和阿根廷分离。携带 bla(CTX-M)的分离株对亚胺培南和美罗培南的药敏率分别为 95.5%和 98.5%,均对替加环素敏感,而 KPC 产生菌对除多黏菌素 B 和替加环素以外的所有检测抗菌药物均高度耐药(药敏率分别为 90.6%和 99.4%)。KPC 和 CTX-M 产生菌的出现迅速增加,尤其是在美国医院,需要扩大治疗选择来治疗这些新出现的病原体引起的感染。